The efficacy of such an approach has been confirmed in another study using murine models injected with a mixture of triple-positive cells, CD19-negative, CD20-negative, and CD22-negative B-cell lymphoma cell lines [109]. This evidence concerns the gene CD22 and B-cell non-Hodgkin lymphoma.